Modelling the Clinical and Complication‐Related Economic Burden of Therapeutic Inertia in People With Type 2 Diabetes in China
Authors' conclusion
Therapeutic inertia in T2DM management imposes quantifiable QALY losses and complication-related cost burdens in China. Timely insulin initiation and intensification significantly improve outcomes and reduce costs
Study context
- Population
- Simulated cohorts of people with T2D in China, baseline HbA1c 9.0%; extrapolated to national population with uncontrolled T2D2 simulated cohorts
- Comparison
- Timely vs delayed insulin initiation and intensification
- Outcome
- Cost savings and QALY gain per patient, timely vs 5-year delay
- Follow-up
- 30-year time horizon
Methodological detailsCORE Diabetes Model, Chinese healthcare system perspective, 30-year time horizon, scenario analyses
- CORE Diabetes Model
- Chinese healthcare system perspective
- 30-year time horizon
- Scenario analyses
Main finding
As reported in the abstract
30-year time horizon
Timely insulin initiation: average saving per patient
¥11 370
Timely insulin initiation: QALY gain
0.086 QALYs
Timely intensification: cost savings per patient
¥10 417
Timely intensification: incremental quality-adjusted life years (QALYs) per patient
0.093 QALYs
Further findings
Population-level savings and QALYs (initiation; intensification)
- Total savings, initiation
- ¥68.2 billion
- Total savings, intensification
- ¥62.5 billion
- Additional QALYs, initiation
- 515 604
- Additional QALYs, intensification
- 557 572
Scenario analyses
- Health and cost benefits increased with higher baseline HbA1c and longer time horizons
Original publication
Modelling the Clinical and Complication‐Related Economic Burden of Therapeutic Inertia in People With Type 2 Diabetes in China. Diabetes Obes Metab. Published 30 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →